NCT05552469 is a Phase 1 clinical trial of DFV890 in Myeloid Diseases, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT05552469?

NCT05552469 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT05552469?

Interventions in NCT05552469: DFV890.

What condition does NCT05552469 study?

NCT05552469 studies Myeloid Diseases.

Is NCT05552469 still recruiting?

NCT05552469 is currently active, enrolled. Last updated 27 March 2026.

Last reviewed 2026-03-27 · How we verify

NCT05552469

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Active, enrolled Phase 1 Last updated 27 March 2026

What this trial tests

Phase 1 trial testing DFV890 in Myeloid Diseases in 62 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 May 2023

Primary endpoint
13 January 2027

13 January 2027

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	62
Start date	8 May 2023
Primary completion	13 January 2027
Estimated completion	13 January 2027
Sites	26 locations across France, Hong Kong, Italy, United Kingdom, Germany, Singapore, United States, Spain

Drugs / interventions tested

DFV890 — full drug profile →

Conditions studied

Myeloid Diseases — all drugs for Myeloid Diseases →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 100, any sex, with Myeloid Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of three groups evaluating DFV890 in patients with myeloid diseases. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, efficacy and recommended dose for single agent DFV890 in patients with lower risk (LR: very low, low or intermediate risk) myelodysplastic syndromes (LR MDS), lower risk chronic myelomonocytic leukemia (LR CMML) and High-Risk Clonal Cytopenia of Undetermined Significance (HR CCUS).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders.
Ramachandran R, Manan A, Kim J, Choi S. · · 2024 · cited 67× · PMID 38945951 · DOI 10.1038/s12276-024-01261-8
NLRP3 and cancer: Pathogenesis and therapeutic opportunities.
Tengesdal IW, Dinarello CA, Marchetti C. · · 2023 · cited 37× · PMID 37866732 · DOI 10.1016/j.pharmthera.2023.108545
The discovery of NLRP3 and its function in cryopyrin-associated periodic syndromes and innate immunity.
Putnam CD, Broderick L, Hoffman HM. · · 2024 · cited 27× · PMID 38146057 · DOI 10.1111/imr.13292
Screening NLRP3 drug candidates in clinical development: lessons from existing and emerging technologies.
Tengesdal IW, Banks M, Dinarello CA, Marchetti C. · · 2024 · cited 21× · PMID 39188718 · DOI 10.3389/fimmu.2024.1422249
Inflammasomes in neurodegenerative diseases.
Wang Q, Yang S, Zhang X, Zhang S, et al · · 2024 · cited 13× · PMID 39710713 · DOI 10.1186/s40035-024-00459-0
Bone marrow microenvironment in myelodysplastic neoplasms: insights into pathogenesis, biomarkers, and therapeutic targets.
Bahmani F, Shayanmanesh M, Safari M, Alaei A, et al · · 2025 · cited 3× · PMID 40349084 · DOI 10.1186/s12935-025-03793-z
Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects.
Li X, Zou C, Xiang X, Zhao L, et al · · 2025 · cited 2× · PMID 40563403 · DOI 10.3390/biom15060761
Molecular Insights and Therapeutic Advances in Low-Risk Myelodysplastic Neoplasms: A Clinical Review.
Dhillon V, Maciejewski J, Balasubramanian SK. · · 2025 · cited 1× · PMID 41300977 · DOI 10.3390/cancers17223610

Verify or expand the search:

Other trials of DFV890

Trials testing the same drug.

NCT06097663 — A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in · Phase 2 · completed
NCT06031844 — A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Parti · Phase 2 · completed
NCT04886258 — Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis · Phase 2 · completed
NCT04868968 — Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS · Phase 2 · completed
NCT04382053 — Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia · Phase 2 · completed

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05552469 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 27 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05552469.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing